Validation of the Moroccan Arabic Version of the Low Anterior Resection Syndrome (LARS) and Wexner Score of Continence Among Rectal Cancer Patients
MA_LARSWEX
Validation of the Morocan Arabic Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction and Wexner Score of Incontinence After Sphincter-preserving Surgery Among Rectal Cancer Patients
1 other identifier
observational
143
1 country
2
Brief Summary
In the past decade, colorectal cancer management improved considerably with total mesorectal excision as well as the multidisciplinary management relying on neoadjuvant radiochemotherapy. This forward leap is currently responsible for an increase in the survivorship of colorectal cancer patients to more than 50% at 5 years. Additively the surgical approach is now more inclined towards sphincter preserving procedures, which allows the conservation of body image but can have negative bowel function repercussions consisting of urgency and incontinence ; all these terms encompassed in the low anterior resection syndrome. In the light of these findings many studies developed assessment tools in order to objectively measure this functional alteration among which are the low anterior resection syndrome questionnaire (LARS) and the WEXNER score. These tools designed to assess bowel function after sphincter-preserving surgery are now translated and validated into various languages and used in different countries. The LARS score relies on the frequency of the symptoms and allows the categorization of patients into 3 groups: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). It assesses the frequency of emptying, incontinence ( liquid, gas ), and other symptoms such as urgency and incomplete voiding. On the other hand, the WEXNER score relies on the examination of the frequency of three types of fecal incontinence (solid, liquid, and gas) and their consequences (pad wearing and lifestyle alteration) with frequency options ranging from never (score 0) through to always (meaning at least once per day; score 4). The score ranges from 0 (perfect continence) to 20 (complete incontinence). The aim of our study is to adapt and validate the LARS and WEXNER score to the moroccan arabic dialect.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2019
Shorter than P25 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2019
CompletedFirst Submitted
Initial submission to the registry
October 13, 2019
CompletedFirst Posted
Study publicly available on registry
October 16, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2019
CompletedFebruary 20, 2020
February 1, 2020
10 months
October 13, 2019
February 18, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Validation of the moroccan arabic version of the LARS score
Validation of the Moroccan arabic Low anterior resection syndrome (LARS) score ; 0 to 20 (no LARS), 21 to 29 (minor LARS ) and 30 to 42 (Major LARS )
6 months after surgery
Validation of the moroccan arabic version of the Wexner score
validation of the Moroccan arabic Wexner score; 0 perfect score and 20 complete incontinence
6 months after surgery
Interventions
Eligibility Criteria
Volantary patient with curative sphincter preserving surgery with no defuntioning stoma who accept to participate in the MA\_LARS and MA\_Wexner scores validation study
You may qualify if:
- Patients aged older than 18 years.
- Neoplasm of the rectum.
- Rectal cancer patients undergoing curative sphincter-preserving surgery with (partial or total) mesorectal excision.
- Surgery performed between January 2012 to March 2019, with reversal of the defunctioning stoma before March 2019;
- Bowel continuity restoration for at least 6 months.
- Consent to participate in the study.
You may not qualify if:
- Palliative surgery.
- The presence of a definitive iliac or perineal stoma.
- Diseases of bowel dysfunction (Crohn's disease)
- Cognitive and/or language issues.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
National Institut of Oncology, Surgical oncology department
Rabat, Please Enter the State Or Province, 10100, Morocco
Private surgical oncology center
Salé, Morocco
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
October 13, 2019
First Posted
October 16, 2019
Study Start
January 1, 2019
Primary Completion
October 31, 2019
Study Completion
October 31, 2019
Last Updated
February 20, 2020
Record last verified: 2020-02